From Medscape Psychiatry

Coverage from the

Alzheimer's Association International Conference (AAIC) 2023

July 16 - 20, 2023; Amsterdam, Netherlands + Virtual

July 16 - 20, 2023 Amsterdam, Netherlands + Virtual

Conference News

AAIC 2023 Reduction in Gut Bacteria Tied to Elevated AD Biomarkers
Medscape Medical News, July 21, 2023
AAIC 2023 Oral Tau Inhibitor Continues to Show Promise in Alzheimer’s
Medscape Medical News, July 21, 2023
AAIC 2023 Volunteering Later in Life Good for the Aging Brain
Medscape Medical News, July 20, 2023
AAIC 2023 Solanezumab for Preclinical Alzheimer's: Phase 3 Data
Medscape Medical News, July 20, 2023
AAIC 2023 Community Memory Screening May Improve AD Diagnosis and Care
Medscape Medical News, July 20, 2023
AAIC 2023 Chronic Constipation Linked to Cognitive Decline
Medscape Medical News, July 19, 2023

AAIC 2023 Cognitive Benefit of Highly Touted MIND Diet Questioned
Medscape Medical News, July 19, 2023
AAIC 2023 Finger-Prick Test Promising for AD Diagnosis, Monitoring
Medscape Medical News, July 19, 2023
AAIC 2023 Opioid Initiation in Dementia Tied to a Major Mortality Risk
Medscape Medical News, July 18, 2023
AAIC 2023 New Evidence Hearing Aids Help Slow Cognitive Decline
Medscape Medical News, July 18, 2023
AAIC 2023 Promising Phase 3 Results for Alzheimer's Drug Donanemab
Medscape Medical News, July 17, 2023
AAIC 2023 US States, Counties With Highest Alzheimer's Rates Flagged
Medscape Medical News, July 17, 2023

Medscape Psychiatry© WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Popular News From AAIC 2022

More Evidence Ultraprocessed Foods Detrimental for the Brain Adding to other recent research showing harmful effects on the brain from eating a diet rich in ultraprocessed food, new findings suggest this type of diet can accelerate cognitive decline.
Medscape Medical News, Aug 01, 2022
Skin Test Accurately Identifies Alzheimer's Disease A minimally invasive skin test, which measures factors related to brain connections, shows high specificity and sensitivity in new research, with diagnoses of Alzheimer disease confirmed at autopsy.
Medscape Medical News, Aug 04, 2022
Negative Antiamyloid Drug Trial: Lessons Learned Although crenezumab was not superior to placebo in individuals who are at high risk for Alzheimer's disease in the API ADAD Colombia Trial, results provide important data for future studies, experts say.
Medscape Medical News, Aug 05, 2022

Previous Coverage

Related Resources

Alzheimer's Disease